OncolaB is an innovative bio-venture company that has developed the next-generation immune-oncology treatment platform ANGel, which possesses excellent drug delivery, efficacy, and sustainability. Founded in May 2024 by CEO Jongseong Kim, who has over 20 years of experience in nanogel research, the company received an investment of $500,000. Additionally, OncolaB was selected as a Deep Tech TIPS company by the Chungbuk Creative Economy Innovation Center, and secured further support of $1,500,000. Our company is developing treatment technologies for difficult-to-treat cancers, including triple-negative breast cancer and various solid tumors, with the following vision.
Company Details
- Founded
- -
- Address
- Boston Convention & Exhibition Center (Bcec)
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://oncolab.co.kr/en/
Oncolab Co. Ltd. Questions
Oncolab Co. Ltd.'s website is https://oncolab.co.kr/en/
Oncolab Co. Ltd.'s LinkedIn profile is https://www.linkedin.com/company/oncolab-co-ltd
Oncolab Co. Ltd.'s industry is
Biotechnology Research
Oncolab Co. Ltd.'s top competitors are
Bioplus Co., Ltd.,
Institut Pasteur Korea Hr,
Neomorph, Inc.,
Accession Therapeutics Limited,
Cha Bio Group｜차바이오그룹,
S-Plane,
Infensa Bioscience,
주식회사 하이스트컨설팅그룹,
Gc Biopharma (Gc녹십자),
Oncolab Diagnostics.
Oncolab Co. Ltd.'s categories are Biotechnology Research
Oncolab Co. Ltd.'s founding year is 2024
